Get the Stockscreener App
5.43
1.63%
-0.09
Amylyx Pharmaceuticals Inc stock is traded at $5.43, with a volume of 755.56K.
It is down -1.63% in the last 24 hours and up +28.37% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$5.52
Open:
$5.52
24h Volume:
755.56K
Relative Volume:
0.87
Market Cap:
$484.03M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
7.7571
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
+24.83%
1M Performance:
+28.37%
6M Performance:
+4.62%
1Y Performance:
+201.67%
1-Day Range:
$5.19
$5.55
1-Week Range:
$4.265
$5.55
52-Week Range:
$1.575
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
5.43 | 387.76M | 380.79M | 49.27M | 10.68M | 0.70 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences - BioSpace
2025-05-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? - Yahoo Finance
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of “Buy” from Analysts - Defense World
2025-05-18 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:AMLX | Press Release - Stockhouse
Dimensional Fund Advisors LP Acquires Shares of 54,114 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Head-To-Head Survey: Perrigo (NYSE:PRGO) versus Amylyx Pharmaceuticals (NASDAQ:AMLX) - Defense World
Mizuho Boosts Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $8.00 - Defense World
Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $7, Maintains Outperform Rating - marketscreener.com
Amylyx (AMLX) Gets Price Target Boost Following Positive Trial Update | AMLX Stock News - GuruFocus
Amylyx price target raised to $8 from $7 at Mizuho - TipRanks
Transcript : Amylyx Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 01 - marketscreener.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2025 Earnings Call Transcript - Insider Monkey
Hsbc Holdings PLC Lowers Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
AMX0035 shows promise in Wolfram syndrome trial By Investing.com - Investing.com South Africa
AMLX Reports Promising Results from HELIOS Trial for Wolfram Syn - GuruFocus
H.C. Wainwright raises Amylyx stock target to $16 on trial hopes By Investing.com - Investing.com South Africa
H.C. Wainwright raises Amylyx stock target to $16 on trial hopes - Investing.com Australia
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome - BioSpace
Amylyx Pharmaceuticals Announces Positive Long-Term Results From Phase 2 Helios Clinical Trial Of Amx0035 In People With Wolfram Syndrome - marketscreener.com
AMX0035 shows promise in Wolfram syndrome trial - Investing.com Australia
Barclays PLC Cuts Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - ACCESS Newswire
2025-05-11 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out | NDAQ:AMLX | Press Release - Stockhouse
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
HC Wainwright Increases Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $16.00 - Defense World
Amylyx Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)April 9, 2024 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AMLX) - Seeking Alpha
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation - Yahoo Finance
Equities Analysts Offer Predictions for AMLX Q1 Earnings - Defense World
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX - ACCESS Newswire
Amylyx Pharmaceuticals (AMLX) Target Price Raised by HC Wainwrig - GuruFocus
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Leerink Partnrs - Defense World
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Leerink Partners - Defense World
Amylyx Pharmaceuticals Inc (AMLX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals Advances Clinical Trials and Strengthens Finances - TipRanks
Amylyx Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Mariner LLC Decreases Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - ACCESS Newswire
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : Amylyx Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
This Biotech Found Mid-Week Success Following Analyst Upgrade - The Globe and Mail
Amylyx Pharmaceuticals Shares Rise After Upgrade From Leerink - marketscreener.com
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):